Overall, the proportion of patients who experienced any grade or grade 3 or higher toxicities did not differ between mutation carriers and wild‐type patients in either cohort (Table 2 and Supporting Information 8), with the exception of grade 1 or higher anemia, which occurred less often in mutation carriers in both cohorts (90% vs 96% (P = .05) and 80% vs 94% (P < .01) for BRCA1 and BRCA2 mutation carriers vs wild‐type patients, respectively). This evidence concerns the gene BRCA2 and anemia (phenotype).